Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma

Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer

(2010) M. Janakiraman et al.   CANCER RESEARCH

Predictive Molecular Markers of Response to Epidermal Growth Factor Receptor(EGFR) Family-Targeted Therapies

(2010) Sarah Barton et al.   CURRENT CANCER DRUG TARGETS

Personalized Medicine in Non–Small-Cell Lung Cancer: IsKRASa Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor–Targeted Therapy?

(2010) Patrick J. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

Roles of Fibroblast Growth Factor Receptors in Carcinogenesis

(2010) E. M. Haugsten et al.   MOLECULAR CANCER RESEARCH

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner

(2009) E di Martino et al.   ONCOGENE

Economic aspects of bladder cancer: what are the benefits and costs?

(2009) K. D. Sievert et al.   WORLD JOURNAL OF UROLOGY

Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer

(2008) Matthew I. Milowsky et al.   BJU INTERNATIONAL

Translation of the Philadelphia chromosome into therapy for CML

(2008) B. J. Druker   BLOOD

Genetic Predictors of MEK Dependence in Non-Small Cell Lung Cancer

(2008) C. A. Pratilas et al.   CANCER RESEARCH